Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation Study of Intranasal Bordetella Pertussis J820 in Healthy Adults
NCT06827470Phase 1Recruiting
- Sponsor
- Dalhousie University
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of Bordetella pertussis J820 (5 arms), sponsored by Dalhousie University. Primary endpoint: Primary Outcome Measures. Started Nov 2025; status: recruiting.
02
Drugs
Bordetella pertussis J820
Beyond the preview
Go deeper on NCT06827470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827470.